// App-Quantinova.ai

4509 : Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.

Researchers

Presenter

  • Bernard J. Escudier

Principal Investigators

  • Padmanee Sharma

  • John Wagstaff

  • Elizabeth R. Plimack

  • Hans J. Hammers

  • Frede Donskov

  • Howard Gurney

  • Jeffrey Alan Sosman

  • Pawel Zalewski

  • Ulrika Harmenberg

  • David F. McDermott

  • Toni K. Choueiri

  • Martin Eduardo Richardet

  • Yoshihiko Tomita

  • Alain Ravaud

  • Justin Doan

  • Huanyu Zhao

  • Helene Hardy

  • Saby George

Medical Centers

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • South West Wales Cancer Institute, Swansea, United Kingdom

  • Fox Chase Cancer Center, Philadelphia, PA

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • Aarhus University Hospital, Aarhus, Denmark

  • Westmead Hospital, Westmead, Australia

  • Vanderbilt-Ingram Cancer Center, Nashville, TN

  • Lakeridge Health, Oshawa, ON, Canada

  • Karolinska University Hospital, Stockholm, Sweden

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Dana-Farber/Brigham and Women's Cancer Center, Boston, MA

  • Oncology Institute of Cordoba, Cordoba, Argentina

  • Niigata University School of Medicine, Niigata, Japan

  • Hopital Saint-Andre, CHU de Bordeaux, Bordeaux, France

  • Bristol-Myers Squibb, Wallingford, CT

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Bristol-Myers Squibb, Lawrenceville, NJ

  • Roswell Park Cancer Institute, Buffalo, NY

Locations

  • Canada

  • Argentina

  • Japan

  • United Kingdom

  • Australia

  • United States

  • France

  • Denmark

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01668784

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved